Which of the following BEST describes how federal regulatory agencies typically make approval decisions?

Question

BlackTom AI · Accepted Answer

Regulatory agencies evaluate the overall balance of benefits and risks when making approval decisions, integrating multiple types of evidence and context.

1. Relevant knowledge points and concepts
- Benefit-risk assessment: weighing therapeutic benefits (efficacy, magnitude, clinical relevance) against risks (safety, adverse events, severity, frequency).
- Types of evidence considered: preclinical data, randomized controlled trials, safety and pharmacovigilance data, manufacturing/quality information, and post‑marketing experience.
- Contextual factors: disease severity, unmet need, available alternatives, patient population, and risk‑management measures.
- Role of experts and cost-effectiveness: advisory input informs interpretation; cost-effectiveness is generally outside regulatory approval criteria (more relevant to payers/HTA).

2. Step-by-step reasoning process
- Step 1: Regulators review clinical efficacy data to determine whether a product demonstrates meaningful benefit.
- Step 2: They review safety data to characterize risks (types, incidence, severity).
- Step 3: They assess manufacturing quality and labeling to ensure consistent supply and appropriate use.
- Step 4: They weigh benefits versus risks in the context of the disease and alternative therapies; they may consider post‑marketing commitments or risk‑mitigation plans.
- Step 5: Advisory committee opinion and expert input may guide the decision but do not replace the data-driven benefit‑risk judgment.

3. Calculations
- No numerical calculations required; the “calculation” is qualitative/quantitative integration of benefit metrics and risk metrics.

4. Why the correct answer is correct
- Option d captures the central regulatory principle: approval is granted when overall benefits outweigh risks for the intended population, possibly with conditions or risk management.

5. Why other options are incorrect
- a. Incorrect: approvals are not based solely on trial/safety results; they also require quality/manufacturing and contextual assessment.
- b. Incorrect: cost‑effectiveness is usually considered by payers/HTA, not a primary regulatory approval criterion.
- c. Incorrect: expert opinion informs decisions but cannot substitute for empirical evidence and formal benefit‑risk evaluation.

6. Conclusion
- Therefore, the best description is d. Based on an overall benefit-risk assessment, which matches the provided answer.

Which of the following BEST describes how federal regulatory agencies typically make approval decisions?单项选择题

类似问题

Name the Supreme Court decision that removed financial constraints on PACs.

Political scientists Joshua Kalla and David Broockman find that senior policy makers made themselves available to _____ between three and four times more often than they did to constituents.

Name the political scientist who argues that parties are designed to serve the needs of ambitious politicians (namely candidates and officeholders).

Name the political scientist who said this famous quote about the problems of pluralism: “The flaw in the pluralist heaven is that the heavenly choir sings with a strong upper-class accent.”

What is the name of the third party candidate in 2000 who was not allowed to participate in the presidential debates? Hint: We watched a video clip with him in class.

E.E. Schattshneider said, "Democracy is ________ save in terms of the parties."

Who was the most recently appointed justice to the Supreme Court?

Name the landmark Supreme Court case that struck down spending limits in federal elections.

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单